Published in FEBS J on October 16, 2009
MicroRNAs in NF-kappaB signaling. J Mol Cell Biol (2011) 2.50
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells. Cancer Res (2011) 2.13
MicroRNAs as biomarkers in colorectal cancer. Am J Pathol (2010) 1.25
miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation. PLoS One (2011) 1.21
Suppression of microRNA-31 increases sensitivity to 5-FU at an early stage, and affects cell migration and invasion in HCT-116 colon cancer cells. BMC Cancer (2010) 1.20
EGFR signals downregulate tumor suppressors miR-143 and miR-145 in Western diet-promoted murine colon cancer: role of G1 regulators. Mol Cancer Res (2011) 1.18
The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Br J Cancer (2011) 1.16
MicroRNA-26b suppresses the NF-κB signaling and enhances the chemosensitivity of hepatocellular carcinoma cells by targeting TAK1 and TAB3. Mol Cancer (2014) 1.14
MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1. J Cell Mol Med (2010) 1.13
Identifying targets of miR-143 using a SILAC-based proteomic approach. Mol Biosyst (2010) 1.12
Changes in microRNA expression in the MG-63 osteosarcoma cell line compared with osteoblasts. Oncol Lett (2012) 1.08
Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci (2012) 1.07
The essential role of evasion from cell death in cancer. Adv Cancer Res (2011) 1.05
Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer (2012) 1.04
Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. BMC Cancer (2012) 1.02
MicroRNAs in colorectal carcinoma - from pathogenesis to therapy. J Exp Clin Cancer Res (2016) 1.00
High-throughput miRNA and mRNA sequencing of paired colorectal normal, tumor and metastasis tissues and bioinformatic modeling of miRNA-1 therapeutic applications. PLoS One (2013) 1.00
MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci (2012) 0.99
Epigenetics Offer New Horizons for Colorectal Cancer Prevention. Curr Colorectal Cancer Rep (2012) 0.97
Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis. Cancer Cell Int (2015) 0.96
MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer. World J Gastroenterol (2014) 0.93
Efficient recovery of proteins from multiple source samples after TRIzol(®) or TRIzol(®)LS RNA extraction and long-term storage. BMC Genomics (2013) 0.92
MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J Cancer Res Clin Oncol (2013) 0.91
MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer. J Biol Chem (2015) 0.90
A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol Ther (2011) 0.90
Glycolysis in Panc-1 human pancreatic cancer cells is inhibited by everolimus. Exp Ther Med (2012) 0.90
Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol Commun (2013) 0.89
MicroRNAs: Clinical Relevance in Colorectal Cancer. Int J Mol Sci (2015) 0.89
Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers. Adv Drug Deliv Rev (2014) 0.88
Implications of microRNAs in colorectal cancer development, diagnosis, prognosis, and therapeutics. Front Genet (2011) 0.88
Non-coding RNAs as theranostics in human cancers. J Cell Biochem (2012) 0.85
The emerging role of microRNAs in drug responses. Curr Opin Mol Ther (2010) 0.85
Annexin-A1 regulates microRNA-26b* and microRNA-562 to directly target NF-κB and angiogenesis in breast cancer cells. PLoS One (2014) 0.84
Down regulation of miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical squamous cancer. Diagn Pathol (2014) 0.84
MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer. Oncotarget (2015) 0.83
Epigenetics meets radiation biology as a new approach in cancer treatment. Int J Mol Sci (2013) 0.83
Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activation. Cell Death Dis (2015) 0.82
MicroRNAs, wild-type and mutant p53: more questions than answers. RNA Biol (2012) 0.82
Clinical implications of microRNAs in cancer. Biotech Histochem (2013) 0.81
Targeting miRNAs for pancreatic cancer therapy. Curr Pharm Des (2014) 0.81
MicroRNA Expression in Selected Carcinomas of the Gastrointestinal Tract. Patholog Res Int (2011) 0.80
Non-coding landscapes of colorectal cancer. World J Gastroenterol (2015) 0.80
Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med (2016) 0.80
miR-143 or miR-145 overexpression increases cetuximab-mediated antibody-dependent cellular cytotoxicity in human colon cancer cells. Oncotarget (2016) 0.79
MicroRNA-195 suppresses colorectal cancer cells proliferation via targeting FGF2 and regulating Wnt/β-catenin pathway. Am J Cancer Res (2016) 0.78
Signature miRNAs in colorectal cancers were revealed using a bias reduction small RNA deep sequencing protocol. Oncotarget (2016) 0.78
Effect of miR-143 on the apoptosis of osteosarcoma cells. Int J Clin Exp Pathol (2015) 0.78
KRAS oncogene repression in colon cancer cell lines by G-quadruplex binding indolo[3,2-c]quinolines. Sci Rep (2015) 0.77
MicroRNAs: an emerging player in autophagy. ScienceOpen Res (2014) 0.77
Characterization of antiproliferative potential and biological targets of a copper compound containing 4'-phenyl terpyridine. J Biol Inorg Chem (2015) 0.76
Signaling of miRNAs-FOXM1 in cancer and potential targeted therapy. Curr Drug Targets (2013) 0.76
MiR-320e is a novel prognostic biomarker in colorectal cancer. Br J Cancer (2015) 0.76
A functional variant rs353292 in the flanking region of miR-143/145 contributes to the risk of colorectal cancer. Sci Rep (2016) 0.76
Targeting KRAS Oncogene in Colon Cancer Cells with 7-Carboxylate Indolo[3,2-b]quinoline Tri-Alkylamine Derivatives. PLoS One (2015) 0.75
Reciprocal regulation between microRNAs and epigenetic machinery in colorectal cancer. Oncol Lett (2017) 0.75
Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective. Curr Colorectal Cancer Rep (2016) 0.75
Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer. Sci Rep (2017) 0.75
miR-1290 Is a Biomarker in DNA-Mismatch-Repair-Deficient Colon Cancer and Promotes Resistance to 5-Fluorouracil by Directly Targeting hMSH2. Mol Ther Nucleic Acids (2017) 0.75
Molecular mechanisms of hepatocellular carcinoma. Hepatology (2008) 3.51
Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients. Am J Gastroenterol (2004) 2.70
Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer (2009) 2.32
miRNA expression in colon polyps provides evidence for a multihit model of colon cancer. PLoS One (2011) 1.72
Gene networks and microRNAs implicated in aggressive prostate cancer. Cancer Res (2009) 1.68
miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol (2012) 1.59
Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells. Cancer Lett (2011) 1.55
MicroRNAs identified in highly purified liver-derived mitochondria may play a role in apoptosis. RNA Biol (2009) 1.55
The role of p53 in apoptosis. Discov Med (2010) 1.46
Emergence of protein kinase CK2 as a key target in cancer therapy. Biofactors (2010) 1.46
Double-stranded siRNA targeted to the huntingtin gene does not induce DNA methylation. Biochem Biophys Res Commun (2004) 1.44
Delivering the promise of miRNA cancer therapeutics. Drug Discov Today (2012) 1.43
Cellular and molecular mechanisms of hepatocellular carcinoma: an update. Arch Toxicol (2012) 1.42
Identification of microRNAs during rat liver regeneration after partial hepatectomy and modulation by ursodeoxycholic acid. Am J Physiol Gastrointest Liver Physiol (2010) 1.38
miR-34a regulates mouse neural stem cell differentiation. PLoS One (2011) 1.37
Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res (2009) 1.36
Genome-wide transcriptional profiling reveals microRNA-correlated genes and biological processes in human lymphoblastoid cell lines. PLoS One (2009) 1.35
Perturbation of 14q32 miRNAs-cMYC gene network in osteosarcoma. Bone (2011) 1.31
Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease. Proc Natl Acad Sci U S A (2002) 1.29
Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci U S A (2003) 1.27
Heme oxygenase-1 gene delivery by Sleeping Beauty inhibits vascular stasis in a murine model of sickle cell disease. J Mol Med (Berl) (2010) 1.23
miR-143 overexpression impairs growth of human colon carcinoma xenografts in mice with induction of apoptosis and inhibition of proliferation. PLoS One (2011) 1.21
Neuroprotection by a bile acid in an acute stroke model in the rat. J Cereb Blood Flow Metab (2002) 1.19
MicroRNAs as gatekeepers of apoptosis. J Cell Physiol (2010) 1.18
Tool from ancient pharmacopoeia prevents vision loss. Mol Vis (2006) 1.17
Regulation of heme oxygenase-1 protein expression by miR-377 in combination with miR-217. J Biol Chem (2010) 1.16
Apoptosis-associated microRNAs are modulated in mouse, rat and human neural differentiation. BMC Genomics (2010) 1.12
Nanocapsule-delivered Sleeping Beauty mediates therapeutic Factor VIII expression in liver sinusoidal endothelial cells of hemophilia A mice. J Clin Invest (2009) 1.11
A facile method for somatic, lifelong manipulation of multiple genes in the mouse liver. Hepatology (2008) 1.09
Evaluation of a new high-dimensional miRNA profiling platform. BMC Med Genomics (2009) 1.08
A novel system for simultaneous in vivo tracking and biological assessment of leukemia cells and ex vivo generated leukemia-reactive cytotoxic T cells. Cancer Res (2004) 1.06
Bile acid levels are increased in the liver of patients with steatohepatitis. Eur J Gastroenterol Hepatol (2008) 1.06
c-Jun N-terminal kinase 1/c-Jun activation of the p53/microRNA 34a/sirtuin 1 pathway contributes to apoptosis induced by deoxycholic acid in rat liver. Mol Cell Biol (2014) 1.06
Genomewide microRNA down-regulation as a negative feedback mechanism in the early phases of liver regeneration. Hepatology (2011) 1.05
Efficient mammalian germline transgenesis by cis-enhanced Sleeping Beauty transposition. Transgenic Res (2010) 1.04
Apoptosis in transgenic mice expressing the P301L mutated form of human tau. Mol Med (2008) 1.03
Combinatorial treatment of DNA and chromatin-modifying drugs cause cell death in human and canine osteosarcoma cell lines. PLoS One (2012) 1.03
Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease. Trends Mol Med (2008) 1.03
Mature hepatocytes exhibit unexpected plasticity by direct dedifferentiation into liver progenitor cells in culture. Hepatology (2012) 1.02
TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-β deposition in APP/PS1 mice. Mol Neurobiol (2012) 1.01
DNA methylation of Sleeping Beauty with transposition into the mouse genome. Genes Cells (2005) 1.01
Neuronal loss in the rostral ventromedial medulla in a rat model of neuropathic pain. J Neurosci (2011) 1.01
p53 interaction with JMJD3 results in its nuclear distribution during mouse neural stem cell differentiation. PLoS One (2011) 1.00
Mature microRNAs identified in highly purified nuclei from HCT116 colon cancer cells. RNA Biol (2010) 0.99
p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis. J Biol Chem (2007) 0.99
Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer's disease mutant neuroblastoma cells. J Neurochem (2006) 0.98
Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes. Am J Physiol Gastrointest Liver Physiol (2007) 0.98
Tumor-induced mechanical hyperalgesia involves CGRP receptors and altered innervation and vascularization of DsRed2 fluorescent hindpaw tumors. Pain (2005) 0.97
Polysome trafficking of transcripts and microRNAs in regenerating liver after partial hepatectomy. Am J Physiol Gastrointest Liver Physiol (2009) 0.97
Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease. Cell Transplant (2002) 0.97
Inhibition of Fas expression by RNAi modulates 5-fluorouracil-induced apoptosis in HCT116 cells expressing wild-type p53. Biochim Biophys Acta (2006) 0.97
Distinct regulatory functions of calpain 1 and 2 during neural stem cell self-renewal and differentiation. PLoS One (2012) 0.96
Tauroursodeoxycholic acid prevents amyloid-beta peptide-induced neuronal death via a phosphatidylinositol 3-kinase-dependent signaling pathway. Mol Med (2004) 0.96
Sleeping Beauty transposition in the mouse genome is associated with changes in DNA methylation at the site of insertion. Genomics (2006) 0.96
Administration of tauroursodeoxycholic acid (TUDCA) reduces apoptosis following myocardial infarction in rat. Am J Chin Med (2007) 0.95
Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry (2003) 0.95
Systemic administration of antisense oligonucleotides simultaneously targeting CK2α and α' subunits reduces orthotopic xenograft prostate tumors in mice. Mol Cell Biochem (2011) 0.94
Endoplasmic reticulum enrollment in Alzheimer's disease. Mol Neurobiol (2012) 0.93
Rat cultured neuronal and glial cells respond differently to toxicity of unconjugated bilirubin. Pediatr Res (2002) 0.93
Targeting the p53 pathway of apoptosis. Curr Pharm Des (2010) 0.92
Efficient recovery of proteins from multiple source samples after TRIzol(®) or TRIzol(®)LS RNA extraction and long-term storage. BMC Genomics (2013) 0.92
Erythroid-specific expression of beta-globin by the sleeping beauty transposon for Sickle cell disease. Biochemistry (2007) 0.92
Apoptosis inducing activity of benzophenanthridine-type alkaloids and 2-arylbenzofuran neolignans in HCT116 colon carcinoma cells. Phytomedicine (2013) 0.91
Dose-dependent differential mRNA target selection and regulation by let-7a-7f and miR-17-92 cluster microRNAs. RNA Biol (2012) 0.91
Inhibition of microRNA-24 expression in liver prevents hepatic lipid accumulation and hyperlipidemia. Hepatology (2014) 0.91
Caspases and p53 modulate FOXO3A/Id1 signaling during mouse neural stem cell differentiation. J Cell Biochem (2009) 0.90
Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid beta-peptide-induced apoptosis of PC12 cells. J Neurochem (2004) 0.90